Calcionics Appoints Daniel O. Wilds Executive Chairman
Advertisement
Calcionics Corporation announced the appointment of Daniel O. Wilds as Executive Chairman of the Company’s Board of Directors. Mr. Wilds is a senior healthcare executive with extensive private and public company leadership and board experience.
Mr. Wilds recently retired as CEO of SCOLR Pharma, Inc. He previously served as Chairman and CEO at Northwest Biotherapeutics, Inc., as CEO at Shiloov Biotechnologies (USA), as CEO of Adeza BioMedical, and as CEO of Medisense, Inc. Mr. Wilds started his career at Baxter International in 1968 where he held various domestic and international senior management positions for more than 20 years including being president of Baxter’s chemotherapy service business and of Travenol-Genentech, a joint venture between Baxter and Genentech. He currently serves on the board of directors of Helix BioMedix, Inc.